FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ralf Clemens

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Procedures

Immunization, Secondary

Disorders

Activities & Behaviors

Travel

Co-author Network

Publications

TOP 3
Pio Lopez; Alexandra Sierra; Sandrine Tilman; Yolanda Caicedo; Ralf Clemens; Angelika Banzhoff
Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule.
Timo Vesikari; Angelika Banzhoff; Astrid Borkowski; Aino Forstén; Nikolaos Gaitatzis; Ralf Clemens
Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Steven Black; Ralf Clemens; Giuseppe Del Giudice; Giovanni Della Cioppa; Markus Knuf; Uwe Nicolay; Theodore Tsai; Timo Vesikari; Rino Rappuoli
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ralf Clemens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pio Lopez; Alexandra Sierra; Sandrine Tilman; Yolanda Caicedo; Ralf Clemens; Angelika Banzhoff
Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule.
Clinical and vaccine immunology : CVI 2013;20(5):753-8.
2012: Timo Vesikari; Angelika Banzhoff; Astrid Borkowski; Aino Forstén; Nikolaos Gaitatzis; Ralf Clemens
Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Human vaccines & immunotherapeutics 2012;8(7):921-8.
2011: Steven Black; Ralf Clemens; Giuseppe Del Giudice; Giovanni Della Cioppa; Markus Knuf; Uwe Nicolay; Theodore Tsai; Timo Vesikari; Rino Rappuoli
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
The Pediatric infectious disease journal 2011;30(12):1081-5.
2011: Timo Vesikari; Peter Wutzler; Frank Baehner; Astrid Borkowski; Aino Karvonen; Dorothee Kieninger-Baum; Markus Knuf; Heinz-Josef Schmitt; Theodore F Tsai; Ralf Clemens
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
The New England journal of medicine 2011;365(15):1406-16.
2011: Theodore F Tsai; Giovanni Della Cioppa; Antonio Crucitti; John Ferguson; Pantaleo Nacci; Uwe Nicolay; Ralf Clemens
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy.
Scandinavian journal of infectious diseases 2011;43(9):702-6.
2011: Theodore F Tsai; Frank von Sonnenburg; Poh Lian Lim; Ralf Clemens
The potential utility of adjuvanted seasonal influenza vaccine for travelers.
Journal of travel medicine 2011;18(4):231-2.
2011: Pio Lopez; Yolanda Caicedo; Alexandra Sierra; Sandrine Tilman; Angelika Banzhoff; Ralf Clemens
Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
The Journal of infectious diseases 2011;203(12):1719-28.
2011: Adriano Arguedas; Carolina Soley; Arturo Abdelnour; Victor Sales; Kelly Lindert; Ralf Clemens; Giovanni Della Cioppa
Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.
Human vaccines 2011;7(1):58-66.
2010: Timo Vesikari; Aino Karvonen; Sandrine Tilman; Astrid Borkowski; Emanuele Montomoli; Angelika Banzhoff; Ralf Clemens
Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Pediatrics 2010;126(4):e762-70.
2010: Theodore Tsai; Moe H Kyaw; Deborah Novicki; Pantaleo Nacci; Saroj Rai; Ralf Clemens
Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.
Vaccine 2010;28(7):1877-80.
2009: Edwin J Asturias; Carlos Mayorga; Carlo Caffaro; Patricia Ramirez; MALATHI RAM; Thomas Verstraeten; Ralf Clemens; Neal A Halsey
Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status.
Vaccine 2009;27(27):3650-4.
2007: Mirta Ciocca; Sandra Fagundes Moreira-Silva; Sylvia Alegría; Maria Cristina Galoppo; Ricardo Ruttiman; Gilda Porta; Themis Reverbel Da Silvera; Pilar Rubio; Mercedes Macias; Yolanda Cervantes; Maria Luisa Avila-Aguero; Sue Ann Costa Clemens; Ralf Clemens; John Weil
Hepatitis A as an etiologic agent of acute liver failure in Latin America.
The Pediatric infectious disease journal 2007;26(8):711-5.
2007: Eliete C Araujo; Sue Ann Costa Clemens; Consuelo S Oliveira; Maria Cleonice A Justino; Pilar Rubio; Yvone B Gabbay; Veronilce B da Silva; Joana D P Mascarenhas; Vânia L Noronha; Ralf Clemens; Rosa Helena P Gusmão; Nervo Sanchez; Talita A F Monteiro; Alexandre C Linhares
Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants.
Jornal de pediatria 2007;83(3):217-24.
2006: Alexandre C Linhares; Thomas Verstraeten; Judith Wolleswinkel-van den Bosch; Ralf Clemens; Thomas Breuer
Rotavirus serotype G9 is associated with more-severe disease in Latin America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(3):312-4.
2006: Markus Knuf; Pirmin Habermehl; J Faber; Hans L Bock; Roland Sänger; H Bogaerts; Ralf Clemens; Anne Schuind; Jean-Baptist du Prel; Heinz-J. (Joe) Schmitt
Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Vaccine 2006;24(27-28):5627-36.
2006: Guillermo Ruiz-Palacios; Irene Pérez-Schael; RAUL VELAZQUEZ; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; jorge salmeron; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
The New England journal of medicine 2006;354(1):11-22.
2004: Sasithon Pukrittayakamee; Kesinee Chotivanich; Arun Chantra; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria.
Antimicrobial agents and chemotherapy 2004;48(4):1329-34.
2003: Sasithon Pukrittayakamee; Sompol Prakongpan; S Wanwimolruk; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.
Antimicrobial agents and chemotherapy 2003;47(5):1509-13.
2003: Olumuyiwa O Odusanya; J E Alufohai; Francois Meurice; Ralf Clemens; V I Ahonkhai
Short term evaluation of a rural immunization program in Nigeria.
Journal of the National Medical Association 2003;95(2):175-9.
2002: Apichart Nontprasert; Sasithon Pukrittayakamee; Arjen M Dondorp; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Neuropathologic toxicity of artemisinin derivatives in a mouse model.
The American journal of tropical medicine and hygiene 2002;67(4):423-9.
2002: Ricardo W Rüttimann; Ralf Clemens
Argentine and Latin American hepatitis A.
Journal of travel medicine 2002;9(4):220.
2002: Anamaria Cavalcanti; Sue Ann Costa Clemens; Frank von Sonnenburg; Françoise Collard; Norbert De Clercq; Robert Steffen; Ralf Clemens
Traveler's diarrhea: epidemiology and impact on visitors to Fortaleza, Brazil.
Revista panamericana de salud pública = Pan American journal of public health 2002;11(4):245-52.
2001: Sasithon Pukrittayakamee; Ralf Clemens; Arun Chantra; Apichart Nontprasert; T Luknam; Sornchai Looareesuwan; Nicholas J White
Therapeutic responses to antibacterial drugs in vivax malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene 2001;95(5):524-8.
2001: Heinz-J. (Joe) Schmitt; R von Kries; B Hassenpflug; M Hermann; A Siedler; W Niessing; Ralf Clemens; J Weil
Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.
The Pediatric infectious disease journal 2001;20(8):767-74.
2000: Sasithon Pukrittayakamee; Arun Chantra; Sirivan Vanijanonta; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria.
Antimicrobial agents and chemotherapy 2000;44(9):2395-8.
2000: Sasithon Pukrittayakamee; Arun Chantra; Julie A Simpson; Sirivan Vanijanonta; Ralf Clemens; Sornchai Looareesuwan; Nicholas J White
Therapeutic responses to different antimalarial drugs in vivax malaria.
Antimicrobial agents and chemotherapy 2000;44(6):1680-5.
2000: H L Bock; Johannes Kruppenbacher; U Bienzle; N A De Clercq; F Hofmann; Ralf Clemens
Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines?
Journal of travel medicine 2000;7(2):74-8.
2000: Sue Ann Costa Clemens; J C da Fonseca; T Azevedo; A Cavalcanti; T R Silveira; M C Castilho; Ralf Clemens
[Hepatitis A and hepatitis B seroprevalence in 4 centers in Brazil].
Revista da Sociedade Brasileira de Medicina Tropical 2000;33(1):1-10.
1999: V Usonis; V Bakasenas; Achim Kaufhold; K Chitour; Ralf Clemens
Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
The Pediatric infectious disease journal 1999;18(1):42-8.
1998: V Usonis; V Bakasenas; K Chitour; Ralf Clemens
Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Infection 1998;26(4):222-6.
1998: Thomas Höhler; Claudius Meyer; A Notghi; Beate Stradmann-Bellinghausen; Peter M Schneider; R Starke; Fred Zepp; Roland Sänger; Ralf Clemens; Karl-Hermann Meyer zum Büschenfelde; Christian Rittner
The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.
Human immunology 1998;59(4):212-8.
1998: Heinz-J. (Joe) Schmitt; Fred Zepp; S Müschenborn; G Sümenicht; Anne Schuind; K Beutel; Markus Knuf; Hans L Bock; H Bogaerts; Ralf Clemens
Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
European journal of pediatrics 1998;157(3):208-14.
1998: E B Keeffe; S Iwarson; B J McMahon; Karen L Lindsay; R S Koff; M Manns; R Baumgarten; M Wiese; Marc Fourneau; Assad Safary; Ralf Clemens; D S Krause
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease.
Hepatology (Baltimore, Md.) 1998;27(3):881-6.
1997: V Usonis; V Bakasenas; P Willems; Ralf Clemens
Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs.
Vaccine 1997;15(15):1680-6.
1997: J A I Weigl; Hans L Bock; Ralf Clemens; Fred Zepp; Pirmin Habermehl; K Beutel; S Müschenborn; G Sümenicht; Anne Schuind; C H von König; A Neiss; S Laukamp; S Kiederle; Heinz-J. (Joe) Schmitt
Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
Annals of the Academy of Medicine, Singapore 1997;26(3):320-5.
1997: Heinz-J. (Joe) Schmitt; K Beutel; Anne Schuind; Markus Knuf; S Wagner; S Müschenborn; H Bogaerts; Hans L Bock; Ralf Clemens
Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age.
The Journal of pediatrics 1997;130(4):616-23.
1997: Ralf Clemens; Roland Sänger; Johannes Kruppenbacher; W Höbel; W Stanbury; Hans L Bock; Wolfgang Jilg
Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance.
Vaccine 1997;15(4):349-52.
1997: Fred Zepp; Markus Knuf; Pirmin Habermehl; Heinz-J. (Joe) Schmitt; Claudius Meyer; Ralf Clemens; Moncef Slaoui
Cell-mediated immunity after pertussis vaccination and after natural infection.
Developments in biological standardization 1997;89():307-14.
1997: Fred Zepp; Heinz-J. (Joe) Schmitt; Achim Kaufhold; Anne Schuind; Markus Knuf; Pirmin Habermehl; Claudius Meyer; H Bogaerts; Moncef Slaoui; Ralf Clemens
Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine.
European journal of pediatrics 1997;156(1):18-24.
1996: Heinz-J. (Joe) Schmitt; Anne Schuind; Markus Knuf; K Beutel; H Schulte-Wissermann; M Gahr; R Schult; J Folkens; W Rauh; H Bogaerts; H L Bork; Ralf Clemens
Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.
The Journal of pediatrics 1996;129(5):695-701.
1996: Heinz-J. (Joe) Schmitt; Anne Schuind; Markus Knuf; Fred Zepp; K Beutel; Carl Heinz Wirsing von König; A Neiss; Hans L Bock; H Bogaerts; Ralf Clemens
Acellular pertussis vaccines: the rationale for an efficacy trial in Germany.
The Journal of infectious diseases 1996;174 Suppl 3():S287-90.
1996: Hans L Bock; J Kruppenbacher; Roland Sänger; W Höbel; Ralf Clemens; Wolfgang Jilg
Immunogenicity of a recombinant hepatitis B vaccine in adults.
Archives of internal medicine 1996;156(19):2226-31.
1996: Fred Zepp; Markus Knuf; Pirmin Habermehl; J H Schmitt; C Rebsch; P Schmidtke; Ralf Clemens; Moncef Slaoui
Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.
Infection and immunity 1996;64(10):4078-84.
1996: Birgit Kallinowski; Hans L Bock; Ralf Clemens; L Theilmann
Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results.
Liver 1996;16(4):271-3.
1996: Sirivan Vanijanonta; A Chantra; N Phophak; D Chindanond; Ralf Clemens; Sasithon Pukrittayakamee
Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria.
Annals of tropical medicine and parasitology 1996;90(3):269-75.
1996: E R Moxon; Ralf Clemens; P Druilhe; J Eskola; O Razum; J Van Hoof
European Commission COST/STD Initiative. Report of the expert panel IV. A common European network for clinical trials.
Vaccine 1996;14(7):624-43.
1996: U Bienzle; Hans L Bock; J P Kruppenbacher; F Hofmann; G E Vogel; Ralf Clemens
Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response.
Vaccine 1996;14(6):501-5.
1996: Heinz-J. (Joe) Schmitt; C H von König; A Neiss; H Bogaerts; Hans L Bock; H Schulte-Wissermann; M Gahr; R Schult; J U Folkens; W Rauh; Ralf Clemens
Efficacy of acellular pertussis vaccine in early childhood after household exposure.
JAMA : the journal of the American Medical Association 1996;275(1):37-41.
1995: Birgit Kallinowski; Hans L Bock; Ralf Clemens; L Theilmann
[Immunogenicity and tolerance of a combined hepatitis A/B vaccine. Preliminary results with a candidate vaccine].
Deutsche medizinische Wochenschrift (1946) 1995;120(42):1426-9.
1995: G Hess; Ralf Clemens; U Bienzle; C Schönfeld; B Schunck; Hans L Bock
Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men.
Journal of medical virology 1995;46(1):40-2.
1995: Ralf Clemens; R Lorenz; Sasithon Pukrittayakamee; B Punpoowang; Sirivan Vanijanonta; P Charoenlarp
Effects of antithrombin III and antivenom on procoagulant activity of Russell's viper venom in a whole blood model.
The Southeast Asian journal of tropical medicine and public health 1995;26(1):143-8.
1995: Ralf Clemens; Assad Safary; A Hepburn; C Roche; W J Stanbury; F E André
Clinical experience with an inactivated hepatitis A vaccine.
The Journal of infectious diseases 1995;171 Suppl 1():S44-9.
1995: Ralf Clemens; Sasithon Pukrittayakamee; Sirivan Vanijanonta; A Nontprasert; Hans L Bock; P Charoenlarp; Nicholas J White
Therapeutic effects of antivenom supplemented by antithrombin III in rats experimentally envenomated with Russell's viper (Daboia russelli siamensis) venom.
Toxicon : official journal of the International Society on Toxinology 1995;33(1):77-82.
1994: Ralf Clemens; C Pramoolsinsap; R Lorenz; Sasithon Pukrittayakamee; Hans L Bock; Nicholas J White
Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway.
British journal of haematology 1994;87(1):100-5.
1994: Sasithon Pukrittayakamee; Sirivan Vanijanonta; A Chantra; Ralf Clemens; Nicholas J White
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
The Journal of infectious diseases 1994;169(4):932-5.
1994: Sasithon Pukrittayakamee; Ralf Clemens; A Nontprasert; Varunee Desakorn; P Charoenlarp; T Chongsuphajaisiddhi; Nicholas J White
Antithrombin III and antivenom reversal of coagulopathy in rats envenomated with Malayan pit viper venom.
Toxicon : official journal of the International Society on Toxinology 1994;32(1):97-103.
1993: R Müller; Hans L Bock; Ralf Clemens; W Jilg
[Active immunization against hepatitis A. Comparison of various immunization schedules].
Deutsche medizinische Wochenschrift (1946) 1993;118(31):1101-4.
1993: U Bienzle; Hans L Bock; W Meister; Ralf Clemens; J P Kruppenbacher
Anti-HAV seroprevalence in German travellers and hepatitis A vaccination in immune subjects.
Lancet 1993;341(8851):1028.
1993: Thomas Weinke; Hans D Nothdurft; H Kretschmer; K Fleischer; T Löscher; B Braendli; K Markwalder; T Schlunk; Ralf Clemens; Hans L Bock
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
Deutsche medizinische Wochenschrift (1946) 1993;118(8):254-9.
1993: Hans D Nothdurft; Ralf Clemens; Hans L Bock; T Löscher
Halofantrine: a new substance for treatment of multidrug-resistant malaria.
The Clinical investigator 1993;71(1):69-73.
1992: Sasithon Pukrittayakamee; Ralf Clemens; C Pramoolsinsap; H E Karges; Sirivan Vanijanonta; Danai Bunnag; Nicholas J White
Polymorphonuclear leucocyte elastase in Plasmodium falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1992;86(6):598-601.
1992: Thomas Weinke; T Loscher; K Fleischer; H Kretschmer; HD Pohle; B Kohler; T Schlunk; Ralf Clemens; Hans L Bock
The efficacy of halofantrine in the treatment of acute malaria in nonimmune travelers.
The American journal of tropical medicine and hygiene 1992;47(1):1-5.
1992: E E Petersen; Ralf Clemens; Hans L Bock; K Friese; G Hess
Hepatitis B and C in heterosexual patients with various sexually transmitted diseases.
Infection 1992;20(3):128-31.
1992: G Hess; V Hingst; J Cseke; Hans L Bock; Ralf Clemens
Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(4):334-40.
1992: W Jilg; R Bittner; Hans L Bock; Ralf Clemens; Hermann M Schätzl; M Schmidt; F E André; F Deinhardt
Vaccination against hepatitis A: comparison of different short-term immunization schedules.
Vaccine 1992;10 Suppl 1():S126-8.
1992: Birgit Kallinowski; K Gmelin; B Kommerell; Hans L Bock; Ralf Clemens; N Scheiermann; B Wohland; F Hofmann; L Theilmann
Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine--a randomized multicentre study with three consecutive vaccine lots.
Vaccine 1992;10(8):500-1.
1991: G Reiner; Ralf Clemens; Hans L Bock; B Enders
Coagulation disorders in experimentally induced acute mouse malaria.
Acta tropica 1991;50(1):59-66.
1990: Sasithon Pukrittayakamee; Varunee Desakorn; Ralf Clemens; A Nontprasert; Hans L Bock; Nicholas J White; Danai Bunnag
Synergy of antithrombin III concentrate and antivenom in preventing coagulopathy in a rat model of Malayan pit viper envenoming.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1990;84(6):880-4.
1989: G Hess; S Rossol; R Voth; D Cheatham-Speth; Ralf Clemens; K H Meyer zum Büschenfelde
Active immunization of homosexual men using a recombinant hepatitis B vaccine.
Journal of medical virology 1989;29(4):229-31.
1989: Sasithon Pukrittayakamee; Nicholas J White; Ralf Clemens; S Chittamas; H E Karges; Varunee Desakorn; Sornchai Looareesuwan; Danai Bunnag
Activation of the coagulation cascade in falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1989;83(6):762-6.
1989: Ralf Clemens; Hans L Bock; B Enders; G Reiner
Antithrombin III substitution affects survival rate in a murine malaria model.
Parasitology research 1989;76(1):36-8.
1988: H E Karges; Ralf Clemens
Factor XIII: enzymatic and clinical aspects.
Behring Institute Mitteilungen 1988;(82):43-58.
1987: Ralf Clemens; E Weidmann; W Merkle; Hans L Bock; R Mauler; J Hilfenhaus
Virus safety of a pasteurized antithrombin III concentrate. Preclinical and clinical data.
Arzneimittel-Forschung 1987;37(7):759-62.